Here are five insights:
1. The Sprint System is the only FDA-cleared percutaneous PNS system indicated for up to 60 days of therapy in the back and/or extremities for chronic and acute pain.
2. The Sprint System is also the industry’s only PNS platform with dual-led capability. The dual-lead capability allows physicians to implant two leads connected to a single wearable pulse generator.
3. Physicians can place the Sprint PNS system leads without surgery, incisions, tissue destruction or anesthesia during outpatient procedures.
4. Preliminary results from a multicenter study evaluating Sprint showed the therapy was associated with significant reduction in chronic post-amputation pain among two-thirds of subjects, after eight weeks of treatment. Four of five patients reported enduring and significant pain relief.
5. SPR Therapeutics aims to advance the early use of neurostimulation as a non-opioid alternative.
More articles on anesthesia:
BlueCross, Anesthesia Medical Group stalemate could cost patients thousands — 6 details
Johns Hopkins panel develops opioid prescribing guidelines for 20 common operations
FDA recalls SpaceLabs anesthesia system 3rd time, for ‘failed state’: 5 details
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.